Hydroquinone: myths and reality

Hydroquinone is widely used in dermatology to address pigmentation disorders. Prior research has shown its effectiveness in inhibiting tyrosinase, a key enzyme in melanin production. However, concerns about safety and side effects have led to uncertainty among clinicians and patients. Established knowledge includes its role in depigmentation and its common use in topical formulations. No prior work had fully resolved the risk-benefit profile of hydroquinone in long-term use. This gap motivated a closer examination of current evidence to guide clinical practice. The need for updated, synthesized information remains unmet in current literature. This paper aims to clarify the evidence base for hydroquinone's use in dermatology.

The aim of this study is to review the latest evidence regarding hydroquinone's efficacy and safety in treating pigmentation disorders. The specific problem addressed is the lack of consensus on optimal formulations and usage guidelines. The motivation stems from the need to provide dermatologists with reliable data to inform patient care. The study focuses on evaluating the strongest evidence from clinical trials and observational studies. It also considers the risk of adverse effects such as exogenous ochronosis. The paper seeks to clarify the role of hydroquinone in combination therapies. The goal is to ensure safe and effective use while minimizing potential harm. This approach supports better-informed clinical decisions in dermatology.

This review synthesizes evidence from contemporary studies on hydroquinone's use in pigmentation disorders. The authors analyze clinical trials and observational data to assess efficacy and safety. They focus on formulations combining hydroquinone with retinoids and corticosteroids. The modified Kligman formula is highlighted as a key example of a triple combination cream. The study evaluates the risk of exogenous ochronosis at concentrations ≤ 5%. Evidence is filtered based on strength, relevance, and tolerability data. The review approach includes comparing outcomes across different formulations and application periods. The authors emphasize the importance of regular monitoring in clinical use.

The strongest evidence supports the use of hydroquinone in combination with retinoids and corticosteroids. The modified Kligman formula is highlighted as the most effective and tolerable formulation. Clinical trials show improved outcomes for hyperpigmentary conditions with this triple combination cream. The risk of exogenous ochronosis remains low when concentrations are ≤ 5%. Regular monitoring is recommended to ensure safety and effectiveness. No significant increase in adverse effects was observed with controlled use. The evidence suggests that hydroquinone can be well-tolerated in appropriate formulations. These findings align with prior research on tyrosinase inhibition and depigmentation.

The authors conclude that hydroquinone remains a valuable treatment for pigmentation disorders when used appropriately. The evidence supports its use in combination with retinoids and corticosteroids. The risk of exogenous ochronosis is low with controlled concentrations and monitoring. Dermatologists should reassure patients about the safety of hydroquinone in clinical settings. The study emphasizes the importance of following prescribed guidelines for application. The findings suggest that hydroquinone can be effective for a range of hyperpigmentary conditions. These conclusions are based on the strongest available evidence from recent studies. The authors propose that continued monitoring is essential for long-term use.